Page last updated: 2024-08-24

repaglinide and Hyperparathyroidism, Secondary

repaglinide has been researched along with Hyperparathyroidism, Secondary in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Akizawa, T; Endo, Y; Fukagawa, M; Kannami, A; Maeda, H; Nagata, Y; Nakamura, H; Narushima, K; Ohtsuka, S; Shimazaki, R; Shiramoto, M; Uchimura, T	1

Trials

1 trial(s) available for repaglinide and Hyperparathyroidism, Secondary

Article	Year
Assessment of CYP-Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans. Clinical and translational science, 2019, Volume: 12, Issue:1 Topics: Administration, Oral; Adult; Alkynes; Benzoxazines; Calcimimetic Agents; Carbamates; Cells, Cultured; Cyclopropanes; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Healthy Volunteers; Hepatocytes; Humans; Hyperparathyroidism, Secondary; Inhibitory Concentration 50; Isoenzymes; Male; Naphthalenes; Oxidation-Reduction; Piperidines; Primary Cell Culture; Pyrrolidines; Theophylline; Young Adult	2019

Article

Year

Assessment of CYP-Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans.

Clinical and translational science, 2019, Volume: 12, Issue:1

Topics: Administration, Oral; Adult; Alkynes; Benzoxazines; Calcimimetic Agents; Carbamates; Cells, Cultured; Cyclopropanes; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Healthy Volunteers; Hepatocytes; Humans; Hyperparathyroidism, Secondary; Inhibitory Concentration 50; Isoenzymes; Male; Naphthalenes; Oxidation-Reduction; Piperidines; Primary Cell Culture; Pyrrolidines; Theophylline; Young Adult

2019